Human growth hormone ($3 billion market, scheduled for Phase III in 2012) that could potentially be injected once a week or twice per month instead of daily injections. GLP-1 / Glucagon dual receptor agonist for Diabetes Type II that could be injected once a week ($2 billion market) that may have dramatically better weight-loss profile than current GLP-1 therapies. Long acting Factor VIIa and Factor IX for hemophilia ($2 billion market). Superior biobetter therapies for patients.
CTP is a small peptide naturally found in the body as a portion of the hormone hCG, and in fact provides hCG with its superior longevity. We attach CTP to other proteins and significantly increase their lonevity as well.
Merck and PROLOR have the exclusive license from Washington University to utilize the CTP technology. On January 28, 2010 the European Commission (EC) gave Merck & Co. marketing approval with unified labeling valid in all European Union Member States for FSH-CTP, now branded as ELONVA®.
Post-Phase II hGH-CTP Study Shows Promise for Regimen in Which 2 hGH-CTP Injections Per Month Could Replace Current Regimen of 30 Growth Hormone Injections Per Month.
Trial of hGH-CTP in Growth Hormone Deficient Adults Achieved Key Efficacy and Safety Endpoints. Positive Results Set Stage for Initiating Phase III Trial Expected to Begin in 2012.
Once or Twice Weekly Injections of PROLOR’s Long-Acting Oxyntomodulin Showed Greater Weight Loss Activity than Two Daily Injections of the Unmodified Version
Patient Enrollment and Dosing On Track for Study Completion by Mid-Year. Review by Independent Data and Safety Monitoring Board Concludes Trial is Safe to Proceed as Planned.
Factor IX-CTP May Provide Hemophilia Patients Prolonged Protection from Bleeding and Enable Reduction in Number of Required Injections to Once-Weekly or Less
"I think Prolor is a great little company, and its small size is one of its main virtues. It is run and managed carefully by hard-working people who get things done efficiently. They currently have half-a-dozen drugs under development, each of which has the potential for over $1 billion in sales."
Data Show PROLOR’s Biobetter Form of hGH has Potential to Reduce Required Dosing Frequency from One Injection Per Day to Two Injections Per Month. Phase I Safety and Tolerability Endpoints Met.
Merck and PROLOR are Both Licensees of the CTP Technology Used to Prolong the Duration of Merck’s Novel Fertility Drug ELONVA®. Supports the Clinical Efficacy and Safety of CTP Technology.
Primate Study Shows Durability of PROLOR’s IFN-Beta-CTP Is Prolonged 13 Times and Drug Exposure is Prolonged 55 Times Compared to Commercially Available IFN-Beta. By Decreasing Frequency of Required Injections, IFN-Beta-CTP Could Provide Important Benefits to Multiple Sclerosis Patients
.gif)
Chairman & CEO of NYSE, Duncan L. Niederauer, hosted a breakfast and bell-ringing ceremony to celebrate PROLOR's recent listing with NYSE